期刊
CLINICS
卷 68, 期 5, 页码 665-673出版社
HOSPITAL CLINICAS, UNIV SAO PAULO
DOI: 10.6061/clinics/2013(05)14
关键词
Endothelial Progenitor Cells; Endothelial Progenitor Cell Inhibitors; Prognosis; Type 2 Diabetes Mellitus; Acute Myocardial Infarction
资金
- National Natural Science Foundation of China [81070195, 81000055]
- Jiangsu Key Laboratory for Molecular Medicine of Nanjing University
- Natural Science Foundation of Jiangsu [GBK2009036, BK2010107]
OBJECTIVE: We aimed to assess the chemotactic response of endothelial progenitor cells to angiotensin-converting enzyme inhibitors in T2DM patients after acute myocardial infarction, as well as the associated prognosis. METHODS: Sixty-eight T2DM patients with acute myocardial infarction were randomized to either receive or not receive daily oral perindopril 4 mg, and 36 non-diabetic patients with acute myocardial infarction were enrolled as controls. The numbers of circulating CD45(-/low+)CD34(+)CD133(+)KDR(+) endothelial progenitor cells, as well as the stromal cell-derived factor-alpha and high-sensitivity C reactive protein levels, were measured before acute percutaneous coronary intervention and on days 1, 3, 5, 7, 14, and 28 after percutaneous coronary intervention. Patients were followed up for 6 months. Chinese Clinical Trial Registry: ChiCTR-TRC-12002599. RESULTS: T2DM patients had lower circulating endothelial progenitor cell counts, decreased plasma vascular endothelial growth factor and alpha levels, and higher plasma high-sensitivity C reactive protein levels compared with non-diabetic controls. After receiving perindopril, the number of circulating endothelial progenitor cells increased from day 3 to 7, as did the plasma levels of vascular endothelial growth factor and stromal cell-derived factor-alpha, compared with the levels in T2DM controls. Plasma high-sensitivity C reactive protein levels in the treated group decreased to the same levels as those in non-diabetic controls. Furthermore, compared with T2DM controls, the perindopril-treated T2DM patients had lower cardiovascular mortality and occurrence of heart failure symptoms (p<0.05) and better left ventricle function (p<0.01). CONCLUSIONS: The use of angiotensin-converting enzyme inhibitors represents a novel approach for improving cardiovascular repair after acute myocardial infarction in T2DM patients.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据